Exelixis Inc
(NAS:EXEL)
$
35.81
-0.04 (-0.11%)
Market Cap: 10.23 Bil
Enterprise Value: 9.24 Bil
PE Ratio: 22.96
PB Ratio: 4.50
GF Score: 91/100 Exelixis Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2019 / 03:40PM GMT
Release Date Price:
$20.05
(+0.30%)
Kyuwon Choi
Goldman Sachs Group Inc., Research Division - Equity Analyst
Okay. Good morning, everyone. I'm Paul Choi, the U.S. SMid Cap biotechnology analyst here at Goldman Sachs. This next session will be with Exelixis, and I'm very pleased to introduce Mike Morrissey, the CEO, who will kick off maybe with a couple of high-level remarks. If that is okay.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Yes. Of course.
Kyuwon Choi
Goldman Sachs Group Inc., Research Division - Equity Analyst
And then we'll dive into Q&A, and at the end we'll reserve a little bit of time for a question or 2 from the audience, if there are any. So...
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
All right. Fantastic. Good morning, everybody. Thanks for joining us today. Before we begin, let me just say that I'll be making forward-looking statements today. So please see our SEC filings for a description of the risks that we face in our
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot